{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:23:36Z","timestamp":1772119416327,"version":"3.50.1"},"reference-count":0,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2003,8,13]],"date-time":"2003-08-13T00:00:00Z","timestamp":1060732800000},"content-version":"vor","delay-in-days":742,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc electrophysiol"],"published-print":{"date-parts":[[2001,8]]},"abstract":"<jats:p> <jats:bold>Midodrine for Neurocardiogenic Syncope. <\/jats:bold>\n          <jats:italic>Introduction:<\/jats:italic> The efficacy of midodrine for the management of patients with neurocardiogenic syncope was assessed prospectively in a randomized control study.<\/jats:p><jats:p> <jats:italic>Methods and Results:<\/jats:italic> Patients who had at least monthly occurrences of syncope and a positive tilt\u2010table test were included in the study. A total of 61 patients were randomly allocated to treatment either with midodrine or with fluid, salt tablets, and counseling. Midodrine was given at a starting dose of 5 mg three times a day and increased up to a dose of 15 mg three times a day when required. Midodrine was given during the daytime every 6 hours. Thirty\u2010one patients were assigned to treatment with midodrine; the other 30 patients were advised to increase their fluid intake and were instructed to recognize their prodromes and abort the progression to syncope. Patients were followed\u2010up for at least 6 months. A quality\u2010of\u2010life questionnaire was administered at the time of randomization and 6 months after. At the 6\u2010month follow\u2010up, 25 (81%) of 31 midodrine\u2010treated patients and 4 (13%) of the 30 fluid\u2010therapy patients had remained asymptomatic (<jats:styled-content>P &lt; 0.001<\/jats:styled-content>). One patient had to discontinue taking midodrine due to severe side effects and another six patients experienced minor side effects that did not require drug discontinuation.<\/jats:p><jats:p> <jats:italic>Conclusion:<\/jats:italic> Midodrine appeared to provide a significant benefit in patients with neurocardiogenic syncope. To prevent recurrence of symptoms, dose adjustments were required in about one third of patients.<\/jats:p>","DOI":"10.1046\/j.1540-8167.2001.00935.x","type":"journal-article","created":{"date-parts":[[2003,8,13]],"date-time":"2003-08-13T14:03:30Z","timestamp":1060783410000},"page":"935-938","source":"Crossref","is-referenced-by-count":139,"title":["Usefulness of Midodrine in Patients with Severely Symptomatic Neurocardiogenic Syncope: A Randomized Control Study"],"prefix":"10.1111","volume":"12","author":[{"given":"ALEJANDRO","family":"PEREZ\u2010LUGONES","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ROBERT","family":"SCHWEIKERT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"STEPHEN","family":"PAVIA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JASBIR","family":"SRA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASOOD","family":"AKHTAR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FREDRICK","family":"JAEGER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GERY F.","family":"TOMASSONI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WALID","family":"SALIBA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FABIO M.","family":"LEONELLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DIANNA","family":"BASH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SALWA","family":"BEHEIRY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JEANNE","family":"SHEWCHIK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PATRICK J.","family":"TCHOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANDREA","family":"NATALE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,8,13]]},"container-title":["Journal of Cardiovascular Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1540-8167.2001.00935.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1540-8167.2001.00935.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T14:35:37Z","timestamp":1700404537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1540-8167.2001.00935.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["10.1046\/j.1540-8167.2001.00935.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1540-8167.2001.00935.x","archive":["Portico"],"relation":{},"ISSN":["1045-3873","1540-8167"],"issn-type":[{"value":"1045-3873","type":"print"},{"value":"1540-8167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}